Question Bank › Event-dense runway

Event-dense runway

Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events

Calls Tested
422
Answered YES
22
Hit Rate
5.2%
rare by design

Archer-Daniels-Midland Company (ADM) — this company's answers

NO on the Q4 2022 call 2023-01-26 C+
The model's full reasoning — Q4 2022 call → NO我们根据规则判断。管理层在电话会议中是否将近期未来描述为公司自身特定、已命名、已安排的事件日历,并将该事件序列作为公司未来发展的核心故事? 检查内容:管理层提到了多个具体事件: - 完成马歇尔现代化、克林顿新磨坊、昆西炼油厂扩建、Rondonopolis柴油厂改进(这些是过去完成时,不是未来) - 北达科他州合资压榨和精炼设施将在今年收获季投入运营(未来事件) - 塞尔维亚替代蛋白扩建完成、西班牙益生菌产能启动(过去完成) - 2023年计划:18个制造设施的自动化项目(已批准范围,但未给出具体时间) - 1ADM业务转型(持续进行,无具体时间) - 脱碳项目(多个,但未给出具体时间表) - 可持续航空燃料、与LG化学的合资(提及但无时间) - 精密发酵(长期) - 2023年资本支出约13亿美元(无具体事件) - 回购10亿美元(无具体事件) 未来事件中,明确时间锚定的只有北达科他州设施(今年收获季)和可能提到的其他?还有“Spiritwood online in Q4”(第四季度上线)和“resume crush in Paraguay”(恢复巴拉圭压榨)——这些在回答分析师问题时提到,但属于公司自身事件。另外“Marshall modernization”是过去完成。还有“we expect our joint venture crush and refining facility in North Dakota to be operational by this year’s harvest”是明确未来事件。 但整体上,管理层的前瞻讨论主要围绕市场条件(需求、利润率、乙醇库存、中国需求等),而不是一系列公司特定事件。虽然提到了几个项目,但并未将它们作为核心叙事。例如,在回答关于2023年展望时,主要讨论市场因素(供应紧张、需求强劲等),然后提到“positive contributions from productivity and innovation initiatives”但未具体化。在回答分析师问题时,提到了一些具体项目,但那是回应问题,不是主动组织。 规则要求:如果前瞻讨论主要关于市场条件、需求、宏观因素、定价或成本控制,而没有公司特定事件日历,则回答NO。这里虽然有少数事件,但并未构成“多个不同、具体、时间锚定的公司特定事件”作为主要引擎。管理层没有将未来季度描述为一系列即将发生的事件序列。因此答案应为NO。

← Back to the full ADM analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that event sequence as the central story of where the company is heading? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent posture: the forward-looking discussion is organized around MULTIPLE distinct, concrete happenings that belong to the company itself and are expected to occur soon — each one identifiable and time-anchored in management's telling (this quarter, next quarter, by mid-year, this season, in the coming months). The events may take whatever form fits the industry — for example: a facility, line, site, store format, or capacity starting up or opening; a product, program, service, or offering launching or shipping; a ramp, rollout, or expansion beginning or reaching its next stage; a first delivery, first production, first cohort, or go-live; a submission, decision, certification, data readout, or approval date; a contract, program, or partnership commencing; a new market or channel switching on. What matters is that (a) there are SEVERAL such distinct company-specific events, not just one; (b) management anchors them in the near term with at least rough timing, presenting them as scheduled or in motion rather than aspirational; and (c) management treats this sequence of upcoming events — rather than general market conditions, demand trends, or cost management — as the main engine of the company's next stage, with the call's forward energy devoted to what is about to happen and how the company is preparing for each step. Answer NO if the forward discussion is chiefly about market conditions, demand strength or weakness, macro factors, pricing, or cost control, with no calendar of company-specific events. NO if there is only ONE meaningful upcoming event, however large. NO if the future items are vague ambitions, pipeline hopes, exploratory initiatives, or opportunities without stated near-term timing. NO if the named events are routine recurring housekeeping this business always has (ordinary seasonal openings at the usual pace, standard annual product refreshes, scheduled maintenance) that management does not present as changing the company's trajectory. NO if management mentions upcoming milestones only in passing while the call's substance is defending current results. NO if the events are mainly things happening TO the company from outside (market recoveries, customer budget cycles, industry conditions) rather than the company's own scheduled actions. NO if the event calendar appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
RCEL AVITA Medical, Inc. Q1 2024 2024-05-14 F
ERO Ero Copper Corp. Q1 2024 2024-05-10 A
LILA Liberty Latin America Ltd. Q4 2023 2024-02-23 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SBS Companhia de Saneamento Básico do Estado Q3 2023 2023-11-10 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
PTLO Portillo's Inc. Q2 2023 2023-08-05 B
BEAT BioTelemetry's Q4 2022 2023-03-17 D
ARWR Arrowhead Pharmaceuticals, Inc. Q4 2022 2022-11-28 D
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
ASTS AST SpaceMobile, Inc. Q2 2022 2022-08-15 D
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
ALKS Alkermes plc Q3 2018 2018-10-23 C
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FATE Fate Therapeutics, Inc. Q3 2016 2016-11-07 C
DUK Duke Energy Corporation Q2 2016 2016-08-04 B

How the model reasoned

PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.

More from the question bank

Second engine igniting off the firstManagement is buying/committing capital at aThe leak is fixed: the company is keeping whDemand pull is outrunning the plan for one sBet-the-company financing already spent on hSaid-then-did: management reports back on itAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.